**Table S1.** Results from the sensitivity analysis where additional covariates were added to the weighted linear and logistic regression modelsa

|  |  |  |
| --- | --- | --- |
|  | **Results from the main analysis** | **Sensitivity analysis with additional variables** |
| Mean change in weight or BMI (Figure 4) |  |  |
| 3-Month Measurement |  |  |
| Weight | MD = -1.49 kg; p = 0.002 | MD = -2.24 kg; p < 0.001 |
| BMI | MD = -0.35 kg/m2; p = 0.048 | MD = -0.58 kg/m2; p < 0.001 |
| Last Measurement |  |  |
| Weight | MD = -1.90 kg; p < 0.001 | MD = -2.09 kg; p < 0.001 |
| BMI | MD = -0.61 kg/m2; p < 0.001 | MD = -0.68 kg/m2; p < 0.001 |
|  |  |  |
| Proportion of patients with weight or BMI increase above threshold (Figure 5) |  |  |
| 3-Month Measurement |  |  |
| Weight |  |  |
| Any weight gain | OR = 0.57; p < 0.001 | OR = 0.41; p < 0.001 |
| ≥5% weight gain | OR = 0.52; p = 0.014 | OR = 0.42; p = 0.004 |
| BMI |  |  |
| Any BMI increase | OR = 0.61; p = 0.003 | OR = 0.46; p < 0.001 |
| ≥5% BMI increase | OR = 0.44; p = 0.003 | OR = 0.38; p = 0.001 |
| Last Measurement |  |  |
| Weight |  |  |
| Any weight gain | OR = 0.58; p < 0.001 | OR = 0.54; p < 0.001 |
| ≥5% weight gain | OR = 0.61; p = 0.014 | OR = 0.53; p = 0.003 |
| BMI |  |  |
| Any BMI increase | OR = 0.38; p < 0.001 | OR = 0.33; p < 0.001 |
| ≥5% BMI increase | OR = 0.51; p < 0.001 | OR = 0.51; p = 0.001 |

**Abbreviations:** ART = antiretroviral therapy; BMI = body mass index; FTC = emtricitabine; MD = mean difference; NRTI = nucleoside reverse transcriptase inhibitor; OR = odds ratio; TAF = tenefovir alafenamide.

**Note:**

a The following variables were added: time since HIV onset, five indicators for exposure to different NRTI backbones during the baseline period (i.e., tenofovir disoproxil fumarate, TAF, FTC, abacavir, and lamivudine), and baseline ART adherence as measured by the proportion of days covered by ARTs during the 12-month baseline period.